Our LuX-Valve is designed to treat symptomatic patients with both severe tricuspid regurgitation and high surgical risk. It is expected to become one of the first TTVR products approved for commercialization in the world. The function of the patient's dysfunctional native tricuspid valve is replaced by a prosthetic valve stent through minimally invasive intervention, which has the advantages of less trauma, less pain, and faster recovery. LuX-Valve was designated as a "breakthrough device" by the FDA, and was the first domestically-developed medical device receiving such designation in the field of heart valve disease treatment.